The psychedelic sector never sits still. Here is what happened during the week of July 21–27, 2025, and why each story matters for the companies and investors we track.
Reunion Neuroscience (—): Reunion publishes RE104 Phase 1 data in the Journal of Clinical Psychopharmacology
Reunion Neuroscience announced peer-reviewed publication of Phase 1 data for RE104, its subcutaneous, shorter-duration serotonergic psychedelic prodrug. The publication supported RE104's pharmacology and tolerability profile ahead of its Phase 2 RECONNECT study in postpartum depression. For the private developer, the journal placement adds scientific credibility to a differentiated, shorter-acting candidate.
Source: globenewswire.com
GH Research (GHRS): GH Research details global pivotal program for GH001 and full Phase 2b TRD dataset
GH Research outlined plans for a global pivotal program for GH001, its inhaled 5-MeO-DMT (mebufotenin) candidate, and released its complete Phase 2b treatment-resistant depression dataset, including a placebo-adjusted 15.5-point MADRS reduction at Day 8 (p<0.0001) and a 73% six-month remission rate in the open-label extension without mandated psychotherapy. The company said only one topic remains on its US FDA clinical hold, tied to respiratory-tract histology findings in rats. The update maps GHRS's path toward Phase 3 while flagging the IND hold as the key US gating item.
Source: globenewswire.com
Clearmind Medicine (CMND): Clearmind initiates leading Israeli site for CMND-100 alcohol-use-disorder trial
Clearmind Medicine completed initiation of a leading Israeli clinical site for its Phase I/IIa trial of CMND-100 in alcohol use disorder, adding to previously activated US sites at Yale and Johns Hopkins. The expansion widened the multinational footprint of the study evaluating safety, dosing and early efficacy signals such as reduced alcohol cravings and consumption. Consistent site build-out is an operational marker of progress for the small-cap.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.